Abraxane, Taxol, Apealea (paclitaxel) is a small molecule pharmaceutical. Paclitaxel was first approved as Abraxane on 1992-12-29. It is used to treat breast neoplasms, kaposi sarcoma, non-small-cell lung carcinoma, and ovarian neoplasms in the USA. It has been approved in Europe to treat breast neoplasms, non-small-cell lung carcinoma, ovarian neoplasms, and pancreatic neoplasms. The pharmaceutical is active against tubulin beta chain. In addition, it is known to target toll-like receptor 4 and nuclear receptor subfamily 1 group I member 2. Paclitaxel's patents are valid until 2034-01-12 (FDA).
|Trade Name||Abraxane, Apealea|
|Indication||breast neoplasms, kaposi sarcoma, non-small-cell lung carcinoma, ovarian neoplasms, pancreatic neoplasms|
|Drug Class||Antineoplastics, taxane derivatives|